SenzaGen subsidiary secures SEK 2.8 million order from existing customer
SenzaGen subsidiary secures SEK 2.8 million order from existing customer
SenzaGen’s subsidiary VitroScreen has secured an order worth SEK 2.8 million from an existing customer for non-animal efficacy testing. The order follows successful assignments during 2026 and reflects VitroScreen’s ability to generate recurring business from major international customers. Testing activities will commence immediately.
The customer is a globally leading supplier of active ingredients for the health and beauty industry. The order comprises multiple non-animal efficacy studies on a range of products and is intended to substantiate product performance and customer benefits.
"A global customer returning with new projects confirms the value of our non-animal efficacy testing services. Recurring business is an important indicator of customer satisfaction and at the same time strengthens our market position within a strategically important area for the Group," says Peter Nählstedt, President & CEO of SenzaGen.
VitroScreen offers preclinical non-animal efficacy testing based on advanced human 3D tissue models and spheroids. The testing generates biologically relevant data that helps customers understand, document, and substantiate the functional performance of their products. These services complement the Group’s offering in regulatory toxicology testing and advisory services.